N oroviruses (NoVs) are the leading cause of severe viral gastroenteritis and are responsible for 50% of all acute gastroenteritis outbreaks in the United States and Europe (3) . Although the severity of disease is usually moderate, lasting 1 to 3 days, infection can be especially virulent in young children, the elderly, and the immunocompromised (2, 18, 21, 22, 24, 35, 40) . It is estimated that 200,000 people die each year from NoV infections, primarily children in the developing world (36) . An effective vaccine would be particularly advantageous for young and aged populations, military personnel, food handlers, child and health care providers, cruise ship passengers, and citizens in the developing world. A central obstacle that blocks NoV vaccine development is the lack of understanding of the extensive antigenic diversity between the large number of NoV strains and the complex interrelationships between host protective immunity and virus antigenic heterogeneity.
NoVs are grouped by the major capsid protein amino acid sequence. Viruses with less than 14.3% difference are classified as belonging to the same strain, those with 14.3 to 43.8% difference are classified as having the same genotype, and those with 45 to 61.4% difference are classified as belonging to the same genogroup (49) . Currently, NoVs are grouped into five genogroups (GI to GV). Viruses of GI and GII are responsible for most human infections. GI and GII are further subdivided into 8 and 21 different genotypes, respectively (3, 49) . Over the past 2 decades, the majority of NoV outbreaks have been caused by strains within the GII.4 genotype. Between 1995 and 2006, four major NoV pandemics associated with evolving GII.4 strains have been documented based on molecular and clinical disease occurrences. During the mid-1990s (34) , strain US95/96 was responsible for ϳ55% of the NoV outbreaks in the United States and 85% of the outbreaks in the Netherlands (46) . In 2002, the US95/96 strain was replaced by the Farmington Hills strain (47) , which was associated with ϳ80% of the NoV outbreaks (19) in the United States. In 2004, the Hunter GII.4 variant was detected in Australia, Europe, and Asia (8, 25, 37) . This strain was subsequently replaced in 2006 by two new cocirculating GII.4 variants in the United States and Europe, Laurens (2006a) and Minerva (2006b) (2, 25, 42) . In 2009, a new GII.4 variant emerged (GII.4 New Orleans), causing the majority of outbreaks in the United States, while the Minerva (2006b) strain also continues to circulate (3) .
NoVs are ϳ38-nm icosahedral viruses with an ϳ7.5-kb singlestranded, positive-sense RNA genome that encodes three large open reading frames (ORFs). ORF1 encodes the replicase polyprotein, while ORF2 and ORF3 encode the major and minor capsid proteins, respectively. Expression of the major capsid protein (ORF2) in baculovirus (23) and Venezuelan equine encephalitis (VEE) virus (4) results in the formation of virus-like particles (VLPs) composed of 180 copies of the monomeric protein (38) . The monomer is structurally divided into the shell domain (S), which forms the core of the particle, and the protruding domain (P) that extends away from the core. The P domain is further subdivided into the P1 subdomain (residues 226 to 278 and 406 to 520) and the P2 subdomain (residues 279 to 405) (38) . P2 represents the most exposed polypeptide on the surface of the viral particle and determines its interactions with potential neutralizing antibodies and with histo-blood group antigens (HBGAs) (10, 12, 28, 29, 32) . The P2 domain of the major capsid protein of GII.4 strains is evolving rapidly, resulting in new epidemic strains with altered ligand binding properties and antigenicity (1, 5, 7, 15, 29, 41, 43) .
To further study GII.4 antigenic variation, we prepared panels of both time-ordered GII. 4 VLPs and mouse monoclonal antibodies (MAbs) to compare epitopes between VLPs that represent various stages of NoV evolution. VLPs were constructed representing each of the pandemic strains (GII. , and a newly emergent GII.4 New Orleans strain (GII. . The lack of cell culture or small-animal models for NoV cultivation has restricted the study of neutralization antibodies and epitopes to in vitro assays that measure the ability of an antibody to "block" the binding of a VLP to an HBGA ligand. This in vitro assay has proven to be highly sensitive, as it differentiates between NoV strains too similar to be distinguished by enzyme immunoassay (EIA). The clinical relevance of the blockade assay, as a surrogate neutralization assay, has been confirmed in both infected chimpanzees (6) and Norwalk virus-infected humans (39) .
Using EIAs and a surrogate neutralization assay based on VLP-HBGA interactions, GII. 4-1987 and -1997 were antigenically indistinguishable from each other as measured by human NoV outbreak sera, VLP-immunized mouse sera, and mouse MAbs (9, 28, 29) . The VLPs of strains circulating post-2002 had significantly less reactivity with sera directed against earlier strain VLPs and minimal reactivity to mouse MAbs directed against GII. . Conversely, selected mouse MAbs generated against GII. reacted only with VLPs that circulated from 2002 or later. These data suggested that the pandemic GII. was an important antigenic hub, while it retained important antigenic features (blockade epitopes) that characterized the first GII.4 pandemic strain, GII.4-1997, it also had new antigenic features (blockade epitopes) that were retained in the 2006 pandemic strain, GII. . No blockade antibodies were found to be in common between GII. 4-1987 and GII.4-2006. To further investigate the complex antigenic profile of the pandemic GII.4-2002 strain, relative to other GII.4 outbreak strains, we created a panel of mouse MAbs directed against GII. and compared the reactivity of these MAbs to that of a panel of time-ordered GII.4 VLPs using EIAs and surrogate neutralization assays. Combining these empirical data with bioinformatic analyses, a GII.4-2002-specific neutralizing epitope was predicted and genetic approaches were used to construct mutant VLPs with chimeric epitopes. EIA and blockade assays were then used to test the mutant VLPs to confirm the unique GII.4-2002 blockade epitope. These data further support the hypothesis that GII.4 NoV evolution results in antigenic variation of "neutralizing" epitopes defined by antibody blockade assays and thus confirms that protective herd immunity is a driving force in NoV evolution.
MATERIALS AND METHODS

VLPs.
A diverse panel of VLPs representing GI and GII NoV strains and epitope E mutants was assembled. Briefly, for all constructs except GII.4 New Orleans, ORF2 constructs were inserted directly into the VEE virus replicon vector for the production of virus replicon particles (VRPs), and VLPs were expressed in VRP-infected BHK cells and purified by velocity sedimentation in sucrose. New clones were verified as approximately 35-nm particles visualized by negative-staining electron microscopy (4, 30) . The GII.4 New Orleans (2009) VLPs were expressed in the baculovirus system and purified by cesium chloride gradient centrifugation. VLP protein concentrations were determined using the BCA protein assay (Pierce).
Mouse immunization, hybridoma production, and IgG purification. MAbs were produced and purified by the University of North Carolina-Chapel Hill Immunology Core (http://mabs.unc.edu). Briefly, to develop the anti-GII. MAbs, Swiss Webster mice were immunized on days 0, 20, 40, and 80 with 50 g of VLP in PBS plus 50 l GERBU adjuvant (Fisher Scientific) for a total of 100 l and splenocytes were fused on day 84. The resulting hybridomas were subcloned by limiting dilution, isotyped (Roche), and purified by protein G chromatography (GE Healthcare).
EIAs. MAb reactivity was determined by EIA as reported previously (26, 28) . Briefly, plates were coated with 1 g/ml VLP in phosphatebuffered saline (PBS) before the addition 2 g/ml purified IgG and incubation, followed by anti-mouse-alkaline phosphatase and color development with pNPP substrate solution (Sigma Chemicals). Each step was followed by washing with PBS-0.05% Tween 20, and all antibodies were diluted in 5% dry milk in PBS-0.05% Tween 20. The EIA data shown in the figures represent the average of at least three replicates, and these data are representative of similar data from at least two independent trials. We established these EIAs using the new MAbs and included PBS and genogroup I VLP-coated wells as negative controls and polyclonal anti-VLP mouse sera as positive controls. Antibodies were considered positive for reactivity if the mean optical density, after background subtraction, of the VLP-coated wells was greater than three times the mean optical density of the PBS-coated wells. A two-way analysis of variance (ANOVA) with Bonferroni's multiple-comparison test was used to compare BT50 values of an antibody with different VLPs. A difference was considered significant if the P value was Ͻ0.05.
HBGA expression in commercial mucins. To characterize the HBGAs present in commercial pig gastric mucin (PGM) type III (Sigma Chemicals), mucin was solvated in PBS at 5 mg/ml and used at 10 g/ml in PBS to coat EIA plates, which were incubated for 4 h at room temperature, and blocked by incubation overnight at 4°C in 5% dry milk in PBS-0.05% Tween 20 before the addition of anti-HBGA MAbs for 1 h of incubation at 37°C. Antibodies to blood group antigen A or B (Ortho Clinical Diagnostics, Rochester, NY) were used at a 1/20 dilution, and antibodies to H, Lewis A, Lewis B, Lewis X (Santa Cruz Biotechnology, Santa Cruz, CA), or Lewis Y (Calbiochem, Gibbstown, NJ) were used at 1 g/ml. Primary antibody incubations were 1 h at 37°C and were followed by a cocktail of anti-mouse IgM/IgG-horseradish peroxidase (HRP; Sigma Chemicals/GE Healthcare) for 30 min at 37°C and color development with 1-Step Ultra TMB (3,3=,5,5=-tetramethylbenzidine) ELISA (enzyme-linked immunosorbent assay) HRP substrate solution. Each step was followed by a washing step (PBS-0.05% Tween 20) , and all of the antibodies were diluted in 5% dry milk in PBS-0.05% Tween 20. Samples were assayed in triplicate. HBGA expression was considered positive if the mean optical density of coated wells, after background subtraction, was greater than three times the mean optical density of PBS-coated wells. As PGM is a crude preparation, the HBGA phenotype of each lot should be verified.
VLP binding to synthetic carbohydrates. Biotinylated synthetic HBGAs (Bi-HBGA; Glycotech, Gaithersburg, MD) were bound to Neutriavidin-coated plates (Pierce) at 10 g/ml for 1 h prior to the addition of 1 g/ml VLP for 1.5 h. VLP binding was detected with a mouse MAb, followed by rabbit anti-mouse IgG-HRP and 1-Step Ultra TMB ELISA HRP substrate (Fisher Scientific). All of the incubations were done at room temperature. Each step was followed by washing with PBS-0.05% Tween 20, and all reagents were diluted in 5% dry milk in PBS-0.05% Tween 20. VLP binding to synthetic HBGAs was considered positive if the mean optical density, after background subtraction (no HBGA coating), of HBGA-coated wells was greater than three times the mean optical density of PBS-coated wells.
VLP binding to PGM. To evaluate VLP binding to PGM, EIA plates were coated with PGM as described above for HBGA expression of PGM. VLPs (1 g/ml) were added to the coated plates for 1 h of incubation, followed by a cocktail of rabbit anti-GI and anti-GII NoV polyclonal sera and mouse MAb anti-GII.4-2006-G6 (28) for 45 min of incubation. Subsequently, a mixture of anti-rabbit/anti-mouse IgG-HRP was added for 30 min of incubation and color was developed with 1-Step Ultra TMB ELISA HRP substrate solution. Each step was followed by washing with PBS-0.05% Tween 20, and all VLPs and antibodies were diluted in 5% dry milk in PBS-0.05% Tween 20. Samples were assayed in triplicate. VLP binding to mucin was considered positive if the mean optical density, after background subtraction, of mucin-coated wells was greater than three times the mean optical density of PBS-coated wells.
Synthetic carbohydrate binding blockade. VLP-HBGA binding blockade experiments were conducted as previously reported by our group (28, 29) , with minor modifications. Synthetic HBGAs were bound to Neutri-avidin-coated plates at 10 g/ml for 1 h prior to the addition of MAb-pretreated VLP at 1 g/ml for 1.5 h of incubation. VLP binding was detected with rabbit anti-NoV antiserum, followed by anti-rabbit-IgG-HRP and TMB substrate. The percent control binding was defined as the binding level in the presence of antibody pretreatment compared to the binding level in the absence of antibody pretreatment multiplied by 100. The HBGA ligands used were H type 3 for GII.4-1987 and B trimer for GII. 4-1997, -2002, -2005, -2006, and -2009 (9, 29) . All of the incubations were done at room temperature. Each step was followed by washing with PBS-0.05% Tween 20, and all of the reagents were diluted in 5% dry milk in PBS-0.05% Tween 20. Two criteria were used to designate an antibody "blockade competent" (28) (i) a positive dose-response relationship between antibody treatment and mean percent control binding, as indicated by a negative slope significantly different from zero by linear regression analysis, and (ii) at least 50% blockade of the VLP-HBGA interaction within the dilution series tested. The 50% blockade titer (BT50) was defined as the lowest MAb concentration tested that blocked at least 50% of VLP binding compared to levels determined in the absence of antibody pretreatment. Samples that did not reach a BT50 by the antibody concentration were assigned a BT50 value equal to 2ϫ the maximum concentration tested for statistical analysis. Serum samples that blocked Ͼ50% binding at the lowest concentration tested were assigned a BT50 value equal to 1/2ϫ the minimum concentration tested for statistical analysis (29) . A one-way ANOVA with Bonferroni's multiple-comparison test was used to compare the BT50 values of an antibody with different VLPs. A difference was considered significant if the P value was Ͻ0.05.
Mucin binding blockade. VLP-mucin binding blockade experiments were conducted as described for VLP-mucin binding and synthetic carbohydrate binding blockade assays, except that antibody-pretreated VLPs were used at 0.5 g/ml and incubated with PGM for 1 h. A blockade antibody was defined as described above.
Western blot analysis. GII.4-2002 VLP was suspended in Laemmli loading buffer, and 9 g of protein was loaded onto a prep-well 7.5% SDS-polyacrylamide gel (Bio-Rad, Hercules, CA). After electrophoresis, proteins were transferred to Immuno-Blot polyvinylidene difluoride (PVDF) membrane (Bio-Rad) and blocked. Immobilized proteins were probed with 1 and 5 g/ml MAb. Antibody-reactive protein was visualized with goat anti-mouse IgG-HRP secondary antibody (GE Healthcare) and the ECL Western blotting detection kit (GE Healthcare). All of the incubations were done at room temperature. Each step was followed by washing with PBS-0.05% Tween 20, and all reagents were diluted in 5% dry milk in PBS-0.05% Tween 20.
Structural models of VLP P domains. The amino acid sequences of GII. 4.1987 , GII.4.2002 , and GII.4.2006 VLPs were individually aligned with the VA387 P domain sequence using ClustalX 1.86 (14) , and the VA387 P domain dimer X-ray crystal structure (PDB accession no. 2OBT) (10) was used as a template for generating homology models. Homology models were generated using the program Modeler available via the Max Planck Institute Bioinformatics Toolkit (http://toolkit.tuebingen.mpg .de/). The structural models were analyzed and compared, and figures were generated using Mac Pymol (Delano Scientific).
RESULTS
Anti-GII.4-2002 MAb reactivity.
The capsid genes of the GII. 4 NoVs are undergoing epochal evolution resulting in phenotypic changes at the level of antigenicity and ligand binding affinity (9, 28, 29) . Our comprehensive study of GII.4 antigenicity over time, utilizing mouse MAbs to the ancestral strain GII. Characterization of a commercially available PGM as a substrate for NoV surrogate neutralization assays. EIAs provide information on the presence or absence of an epitope on a VLP. Neutralization assays provide information on the function of an antibody in protection from infection. In the absence of a cell culture model, blockade of VLP binding to Bi-HBGAs has been used extensively as a NoV surrogate neutralization assay (20, 27, 28) . However, the high cost, limited availability, and limited diversity of commercial synthetic HBGAs have hampered progress in the field. Robust human NoV VLP binding to PGM has been reported (44, 45) , reflecting the native HBGA milieu in biological samples. To determine if commercial mucin preparations could serve as a biochemically semicharacterized HBGA ligand source in surrogate neutralization assays, we first characterized the HBGA distribution of semipurified PGM type III using MAbs to H antigen, Lewis A antigen, Lewis B antigen, Lewis X antigen, Lewis Y antigen, A antigen, and B antigen. In agreement with previous reports of HBGA distribution in individual animals (11), PGM was positive for relatively high levels of H and A antigens and more moderate levels of Lewis Y antigen ( Fig. 2A) . Lewis A, Lewis B, Lewis X, and B antigens were not detected (11) . These data suggest that PGM may have broad NoV VLP binding properties because of abundantly available ␣-1,2-fucose (H antigen) and ␣-1,4-fucose (Lewis antigen) moieties. GII. 4 VLPs from 1987 to 2002 have all been reported to bind to at least one of the HBGAs abundant in PGM (29) . However, synthetic HBGA binding ligands for GII. 4-2004, -2005 , and -2009 VLPs have not been reported. Therefore, the carbohydrate binding profile of these VLPs was determined (Fig. 2B) . GII. bound to H type 3, Lewis Y, and B trimer (29, 48) . Consistent with our previous report (29) , a ligand binding partner for GII.4-2004 VLP was not identified in this assay, perhaps reflecting residue microvariation occurring within the different GII. Hunter strains used by different laboratories or the difference between VLP binding compared to P particle binding (29, 48) . MAb based detection reagents identified GII. To confirm this suggestion, the panel of GII.4 time-ordered VLPs was tested directly for PGM binding. VLP binding to PGM was consistent with synthetic HBGA binding profiles. All of the VLPs tested, except GII.4-2004, bound to H, A, and/or Lewis antigens in the synthetic HBGA assays (Fig. 2B) (9, 29) , and all VLPs tested, except GII.4-2004, bound to PGM (Fig. 2C) at a 1 g/ml VLP concentration. The HBGA binding characteristics of GII. have been reported as either less robust than other GII.4 strains using P particles (48) or below the limit of detection using VLPs (Fig. 2B) (Fig. 2D) . Threefold more VLP (3 g/ml) than the other GII.4 VLPs (1 g/ ml) was required to detect binding of GII. (Fig. 3) . Anti-GII.4-2002-G6 did block homotypic VLP interactions (BT50, 0.08 g/ml) (Fig. 3) but was unable to block any other GII.4 VLP interaction with synthetic HBGAs (Fig. 4) . In agreement with Bi-HBGA blockade results, anti-GII.4-2002-G6 efficiently blocked the GII.4-2002 VLP-PGM interaction (BT50, 0.08 g/ml) (Fig. 5) . This blockade was selective, as the antibody had no effect on the GII.4-1987 or GII.4-1997 VLP interactions with PGM or Bi-HBGA (Fig. 4 and 5 (Fig. 6 ). These data, combined with EIA data demonstrating broad GII.4 reactivity of GII.4-2002-G1, -G2, -G3, and -G4, suggest that these antibodies may recognize highly conserved linear epitopes and may be suitable for diagnostics.
Epitope mapping of anti-GII.4-2002-G6. Previous work has indicated that blockade epitopes are located in the P2 subdomain and are likely dependent on the appropriate confirmation (17, 28, 31) . Bioinformatic analyses identified five putative epitopes based upon variation that maps to the P2 subdomain surface of the NoV capsid (16) . Epitope E, composed of surface-exposed residues 407, 412, and 413, is located in the P2 subdomain lateral to the receptor binding sites on the top of the surface. Because epitope E is located distal to the other epitopes, encodes significant amino acid change over time, and varies among 1987, 2002, and 2006; this putative epitope was selected for further characterization (Fig. 7) . Using the GII. (Fig. 1B) . Epitope E of the nonreactive GII. (Fig. 8C and  D) . However, exchanging the entire epitope E sequence and amino acid 412 alone between the reactive and nonreactive GII.4 Modeling of amino acid variation in epitope E over time. Residues 407, 412, and 413 were identified as key amino acids that were exposed to the surface and that changed frequently over time, suggesting a role in escape from herd immunity. Because a potential MAb binding site is larger than three amino acids, residues within 8 Å of the key amino acids were analyzed to determine the impact of amino acid replacements at positions 407, 412, and 413 on the local structural neighborhood. This distance was selected because it accounted for most of the residues that were localized around the E epitope and included all of the residues that would likely be directly impacted by changes at positions 407, 412, and 413. By expanding from these three sites to include residues within 8 Å of those sites, additional variations at positions 355 to 357 were noted (Fig. 9) .
Modeling of the predicted impacts of amino acid variation provides potential mechanistic insights into antibody-VLP interactions at a specific site. Structural modeling predicted that the primary interaction between GII.4.2002 and MAb GII.4-2002-G6 appears to be amino acid R411, which is invariant among GII.4 strains after 1977 (Fig. 9) . Importantly, R411 appears to extend from the surface of the GII. (Fig. 9) . Structural studies on cocrystals are needed to validate these predictions. (Fig. 9D, E, and F) .
DISCUSSION
Understanding the molecular mechanisms governing GII.4 antigenic variation is key to designing immunotherapeutics and vaccines and developing diagnostic predictions regarding the epidemic potential of newly emergent strains. The study of antigenicity among related GII.4 NoV strains using mouse MAbs developed against a time-ordered panel of GII.4 VLPs has demonstrated two important findings relative to NoV vaccine design. First, the major antigenic determinant of GII.4 NoVs (the major capsid protein) is undergoing antigenic variation over time. Second, antibodies can be developed that recognize and potentially neutralize a broad range of GII. These data indicate that a successful NoV vaccine regimen will For three MAbs, the reactivity extended to other GII VLPs. The four broadly reactive MAbs detected denatured capsid protein by Western blot analysis, suggesting that these antibodies recognize linear epitopes that are conserved within the genotype. These data suggest that these antibodies (anti-GII.4-2002-G1, -G2, -G3, and -G4) do not recognize neutralizing epitopes, and although not informative about viral antigenic evolution, they do provide potential diagnostic reagents for detection of broader groups of NoV strains. These antibody reactivity patterns are reminiscent of those generated by immunizing mice with P particles (48) , as the antibodies react with denatured capsid protein by Western blot analysis but did not block VLP-ligand interactions. These data underscore an important complication of using Western blot analysis to determine the antigenic relatedness of GII.4 strains. As all of the blockade antibodies we have identified to date (Fig. 4 to 6 ) (28) 4-2002 ). An interesting feature of epitope E is its location on the surface of the NoV capsid. Unlike other predicted GII.4 epitopes, this epitope resides lateral to the HBGA binding site. In contrast to the carbohydrate binding pockets that occur directly on top of the P2 subdomain; residues 407, 412, and 413 are positioned on the side of the P2 subdomain extending away from the surface. However, expanding the epitope to include all amino acid residues within 8 Å of residues 407, 412, and 413 revealed a second region proximal to these sites that includes residues 355 to 357, which are more exposed to the top of the P2 subdomain. We hypothesize that these residues are part of the same epitope as residues 407, 412, and 413. The inclusion of these residues in an expanded epitope E suggests that MAb GII.4-2002-G6 blocks the ability of the VLP to interact with its ligand by direct hindrance of the binding pocket. Mutants have been designed to determine if amino acid positions 355 to 357 and 407, 412, and 413 make up a single epitope.
Other GII.4 epitopes have been predicted using bioinformatic methods (16) and mapped using molecular biological approaches (14a). Allan et al. (1) recently compared the reactivities of five MAbs against a pre-and post-2002 epidemic GII.4 strain and identified a conformational epitope(s) composed of residues 294 to 296 and 393 to 395. Interestingly, both of these regions were previously predicted to be epitopes using bioinformatic methods (1, 16, 28) and were later verified by molecular analyses (1, 29) . The carbohydrate blockade potential of these antibodies was never tested, so the role of this site in escape from herd immunity is uncertain. Unfortunately, none of our VLPs allowed a direct comparison between the two studies but the finding that residues 393 to 395 were antigenically important supported our previously published work identifying amino acid 395 as an antigenic determinant in the GII.4-2002 Farmington Hills strain (29) .
Blockade of VLP binding to biotinylated synthetic HBGAs has been used extensively as a NoV surrogate neutralization assay by our group and more recently by others. The key limitation of this assay is the commercial availability of biotinylated HBGAs, which occasionally suffer from inconsistent product availability, variable quality control, and limited offerings compared to the diversity of the biological molecules. Human salivary samples are a potential source of biologically relevant HBGAs, but collection is hampered by the need for institutional review board approval and donor collection (26) . Further, each human salivary sample contains variable components in variable quantities/time, depending on an individual's genetics and behaviors, making it nearly impossible to develop a standardized sample pool for the NoV field. To address these limitations, we devised an antibody-mediated VLP-PGM blockade assay based on the ability of NoV VLPs to bind to com-
FIG 9
Variation in epitope E alters capsid structure. Epitope E was defined by variable residues 407, 412, and 413 (406, 411, and 412 for GII. 4.1987 ) and all residues within 8 Å of these sites, as these additional residues are likely to be impacted by the structural differences (driven by the variable sites) that contribute to MAb recognition differences. GII. . R411 is nearly identical, suggesting that N412T frees the R411 side chain to extend away from the surface, where it likely interacts with the MAb. Resides that regulate R411 make up site 1, and 87% of binding can be recovered with structural modifications to R411. A second site, site 2, is composed of residues 355 to 357, and particularly D355, which adds negative potential to the second site.
mercially available, semipurified PGM (45) . By nature, the composition of gastric mucin is complex and each lot may require HBGA phenotyping before use as a substrate, but it is inexpensive and available in semipurified lots, providing a platform for the evaluation of VLP-carbohydrate interactions. We used antihuman HBGA MAbs to phenotype the HBGA content of semipurified PGM. These antibodies confirmed the presence of ␣-1,2-fucose (H antigen), ␣-1,4-fucose (Lewis antigen), and A antigen for VLP binding. B antigen was not detected, confirming previous reports of porcine HBGA expression (11) . Clearly, the lack of expressed B antigen limits the depth of the assay, but it does not limit the functionality of the assay, as all of the VLPs tested by our group and others bind to H, Lewis, or A antigen. Previously, binding of NoV VLPs to HBGAs has been shown to be dependent upon the valency of the carbohydrate (33) . Our PGM binding data support this observation. VLP binding to PGM is stronger than binding to synthetic HBGAs, allowing us to use half as much VLP per binding assay and still maintain robust binding signal/noise ratios. For example, GII.4-2004 binding to PGM was detected at 3 g/ml but binding to synthetic HBGA was not detected at 5 g/ml. To establish the VLP-PGM blockade assay, the blockade potential of anti-GII.4-2002-G6 was characterized using both the traditional biotinylated HBGAs and the PGM blockade assay. These finding have been replicated for additional panels of anti-NoV MAbs not raised against GII. . The response curves of both assays were similar for all of the MAbs and polyclonal sera tested (data not shown), indicating that PGM provides a blockade assay platform that is affordable and readily available for use in the increasing numbers of labs interested in NoV surrogate neutralization assays.
The lack of availability of quality-controlled, diverse, biotinylated HBGAs not only impacts the ability of the research community to access potential neutralization of anti-NoV antibodies, it also impacts the key assay used to characterize HBGA binding profiles of NoV strains. Conflicting data on GII.4 ligand binding patterns produced from different labs has been controversial in the NoV field. Even though a consensus is forming around the acknowledgment that altered ligand recognition occurs within the GII.4 strains over time (29) , it is important to also acknowledge that GII.4 ligand recognition varies by assay as no two labs have exactly the same set of assay reagents, reagent concentrations, or conditions. Even within our own set of reagents, we have discovered that the choice of detection antibody can impact ligand binding results. Utilizing MAbs rather than polyclonal sera for detection increased the assay sensitivity enough to detect lower levels of biotinylated-HBGA binding. As has been demonstrated repeatedly, one amino acid difference within the P2 domain can significantly alter VLP-HBGA affinity (13, 15, 29) ; therefore, making comparisons between data sets is misleading without the accompanying P2 subdomain sequence information.
The data presented here on GII.4-2002-HBGA binding and antigenicity support our hypothesis that GII.4 NoV strains persist in human populations by altering their affinity for HBGA ligands in response to antibody-driven antigenic variations. Both of these features are mediated by epochal evolution of the major capsid protein. Use of MAbs and blockade assays allowed us to demonstrate that the pandemic GII.4-2002 strain is antigenically distinct from the previous pandemic strain GII.4-1997 and the following pandemic strain GII. , indicating that new pandemic strain emergence is associated with changes in neutralizing epitopes. Identification of a novel GII.4 blockade epitope provides a target for monitoring new strain emergence and potential therapeutics. Finally, the identification of these evolving epitopes will provide key targets for effective vaccine redesign, allowing the rational reformulation of existing vaccine components to target newly emerged contemporary strains over time.
